

4

6





M	IOMEI	VTUM	2022 Annual Conference and T	rade Show <sup>*</sup> August 30 – Septemb	LeadingAge* Ohio
The Hospice Medicine Toolkit					
	Acetaminophen	Alprazolam	Atropine	Bisacodyl	Chlorpromazine
	Dexamethasone	Haloperidol	Hydromorphone	Lorazepam	Methadone
	Morphine	Oxycodone	Phenobarbital	Prednisone	Senna
					4


MOI	MENTUM,	Leading Age  Ohio  122 Annual Conference and Tesle Show - August 30 - September 1, 2022
What Fa	actors Drive Medi	cation Choice?
	Favorable clinica PK/PD profile	Acceptance from patient/family/ prescriber
		dication Choice
	Versatility	Cost

Leading Age Ohio Pharmacokinetic and Pharmacodynamic Considerations Pharmacokinetics (PK) What the body does to the drug
 Absorption, distribution, metabolism, elimination Pharmacodynamics (PD) What the drug does to the body
 Therapeutic effects, adverse effects, duration and intensity of effects

5







What Factors Drive Medication Choice?

Favorable clinical PK/PD profile


Medication Choice

Versatility

Cost

Cost


9 10





Patient Specific Factors


What are the patient's goals and expectations?
What are the patient's comorbidities? Medication allergies?
What medications is the patient's laready taking?
What is the patient's expected prognosis? Swallowing capabilities? Ambulatory status?
What is the patient's caregiver situation?

11 12













15 16






17 18







Cost

What does cost effectiveness mean?

Not only affordable, but also effective

Cost-effectiveness analysis

Compares both cost and health outcomes of a treatment to alternative treatments

Cost-effectiveness research

Conducted alongside efficacy, safety, tolerability research


Assigns value to medications


Determines the least costly and most effective way to achieve positive health outcome


Goal = efficient use of healthcare resources

22

21








Essential Medications in Hospice Care

25 26




What are the Goals of Symptom Management?

Improve patient quality of life
Use medications efficiently
Minimize medication side effects
Execution dosing regimens simple
Anticipate disease progression
Provide information and choices to the patient and caregivers


28

27






29 30




Leading Age Morphine Pharmacologic Category: Opioid · Uses: Pain, dyspnea, cough Starting Dose Immediate-release: 2.5-5 mg PO/SL/PR q4h PRN Extended-release: 15 mg PO/PR q12h Adverse Effects Boxed Warnings: addiction, abuse and misuse; respiratory depression; accidental injection; risk of medication errors (oral solution); concomitant CNS depressants Somnolence, constipation, nausea, hypotension, vomiting, dry mouth, urinary retention, pruritis, respiratory depression, opioid-induced neurotoxicity Monitoring Parameters
 CNS side effects, vitals (including respiratory rate)

31 32




Leading Age **Short-Acting Opioids** Versatile and cost-effective Concentrated oral solution allows for easy administration in patients with difficulty swallowing Use caution in patients with renal impairment Morphine 2.5-5 mg PO/SL/PR q4h PRN for pain or shortness of breath Lowest-dose of immediate-release tablets is 15 mg Lowes: oose of immediate-release tainets is 15 mg
Preferred immediate-release opioid in patients with renal
impairment
Concentrated oral solution is costly
Frequency of combination products (oxycodone/acetaminophen)
are limited due to maximum daily doses of acetaminophen
Conscientific in family lice of concentrated. 2.5 mg PO/SL/PR q4h PRN for pain or 1 mg PO/SL/PR q4h PRN for pain or Hydromorphone Oral solution (1 mg/mL) is not concentrated Use caution in patients with renal impairment

34



Leading Age Patient Case: Susan Mrs. Elliot is 84 years old with end stage COPD, CVA, dysphagia, diabetes, and Stage IV CKD. She has decided to elect hospice care at home. She is too short of breath to ambulate and says her breathing is not controlled despite optimal inhaler use. She is hesitant to use morphine because she received it in the hospital and it made her feel loopy. She is opioidnaïve. What is the best choice for Mrs. Elliot to palliate her shortness of breath? a) Oxycodone 20mg/ml oral concentrate 2.5 mg (0.125 mL) PO/SL q4h PRN for shortness of breath or pain Hydromorphone 1mg/ml oral solution 1 mg (1 mL) PO/SL q4h PRN for shortness of breath or pain Oxycodone 5mg tablet 2.5 mg (1/2 tablet) PO/SL q4h PRN for shortness of breath or pain Morphine 20mg/ml oral concentrate 5 mg PO/SL q4h PRN for shortness of breath or pain



Leading Age. Methadone Drug-Drug Interactions
 CYP 3A4 and 2B6 (inducers and inhibitors)
 QTC Prolonging Medications CNS Depressants Clinical Pearls  $\label{lem:methodone} \begin{tabular}{ll} Methodone is not as commonly used outside of hospice and palliative care so prescribers may not be as comfortable with dosing \end{tabular}$ comfortable with dosing

Methadone has a long half-life


Caution with initiation and dose titration

Avoid use for shortness of breath; reserve methadone for pain management

Available as an oral solution or an oral tablet (may be crushed)

Only 5 mg and 10 mg tablets may be used for pain management

37 38





Leading Age Common Anticholinergics in Hospice Care Atropine · Hyoscyamine • Glycopyrrolate Scopolamine


40

MON	MENTU	LeadingAge Ohio
Anticho	linergics	
Anticholinergics	Initial Dosing	Clinical Pearls
Atropine 1% ophthalmic solution	2 drops SL q4h PRN	1 <sup>st</sup> line treatment for terminal secretions are non-pharmacologic interventions     18 ophthalmic solution is given sublingually, educate caregivers about non-standard route     Easy dosage formulation for caregivers to administer
Hyoscyamine	0.125 mg SL q4h PRN	1a line treatment for terminal secretions are non-pharmacologic interventions     ODT are easier to administer than oral tablets
Glycopyrrolate	1 mg PO q8h PRN	Bioavailability is low; poor choice to give orally for terminal secretions     May be useful for treating chronic sialorrhea     Fewer CRS adverse effects (sedation, confusion)     Oral solution is costly     Injectable preparation may be useful for management of bowel obstruction (oral dosing is not equivalent to IV)
Scopolamine	1 patch q72h TD	Should not be used for terminal secretion management due to slow onset of action     If using for chronic sialorrhea, rotate patch site to avoid skin irritation
Protus, 2015; LexiComp, 20	21	41

Leading Age Ohio Common Antiemetics in Hospice Care • Haloperidol Promethazine • Prochlorperazine









Common Antipsychotics in Hospice Care

• Haloperidol
• Chlorpromazine
• Quetiapine
• Risperidone

45 46


MUN	ENTUM	Leading Age Onio 2022 Annual Conference and Telds Show: August 30 - September 1, 2022
Antipsyc	hotics	
Antipsychotic	Initial Dosing	Clinical Pearls
Haloperidol	0.5 mg PO/SL/PR q6h PRN	Versatile; available as an oral concentrate (2 mg/mL), oral tablets or injectable Avoid use in Parkinson's disease or LBD Also useful for nausea/vomiting Cost-effective medication
Chlorpromazine	10 mg PO/SL q8h PRN or ATC	More sedating than haloperidol     Use in caution in ambulatory patients due to risk of orthostatic hypotensio     One of the antipsychotics with highest risk for seizure     Avoid use in Parkinson's disease or LBD
Quetiapine	25 mg PO BID	Preferred antipsychotic in patients with Parkinson's disease or LBD     Most sedating of the atypical antipsychotics     Limited dosage formulations
Risperidone	0.25 mg PO BID	Available as an oral solution, ODT, or oral tablet; ODT more expensive than traditional tablets     May have some benefits for nausea when haloperidol in shortage








Leading Age Common Laxatives in Hospice Care Senna • Docusate and Senna Bisacodyl

50 49











### Patient Case- Bobby

Bobby is a 72-year-old male on hospice with a primary diagnosis of lung cancer with metastases to the bone. Bobby is experiencing significant issues with shortness of breath, even at rest. Other past medical history includes hypertension and depression.

#### Current medications:

- Albuterol 1 unit via nebulizer q4h PRN Lisinopril 10 mg PO once daily

- Prednisone 20 mg PO once daily Prednisone 20 mg PO once daily Morphine 2.5 mg PO q4h PRN dyspnea

What additional comfort medication should be added to Bobby's profile at this time?

- a) Lorazepam 0.5 mg PO q4h PRN for
- b) Haloperidol 0.5 mg PO q4h PRN for nausea/vomiting
- c) Senna 8.6 mg tablets 2 tablets PO once daily at bedtime PRN for opioid-induced constipation
- d) Atropine 1% ophthalmic solution 2 gtts SL q4h PRN for terminal secretions

Leading Age

## Patient Case- Bobby

Bobby is a 72-year-old male on hospice with a primary diagnosis of lung cancer with metastases to the bone. Bobby is experiencing significant issues with shortness of breath, even at rest. Other past medical history includes hypertension and depression.

#### Current medications:

- Albuterol 1 unit via nebulizer q4h PRN

- Lisinopril 10 mg PO once daily Sertraline 100 mg PO once daily Prednisone 20 mg PO once daily Morphine 2.5 mg PO q4h PRN dyspnea
- What additional comfort medication should be added to Bobby's profile at this time?
- a) Lorazepam 0.5 mg PO q4h PRN for nausea/vomiting
- b) Haloperidol 0.5 mg PO q4h PRN for nausea/vomiting
- c) Senna 8.6 mg tablets 2 tablets PO once daily at bedtime PRN for opioid-induced constipation
- d) Atropine 1% ophthalmic solution 2 gtts SL q4h PRN for terminal secretions

55

56



### **Key Points**

- The key factors that affect why we use the medications we use include favorable clinical pharmacological properties, versatility, patient and provider acceptance, and cost.
- Ideal medications can treat multiple symptoms at the same dose, can be given via multiple routes of administration, and have minimal side effects at the therapeutic dose
- Not all patients are candidates for these common medications. Medication selection and treatment for all symptoms should be patient-centered.

MUMENTUM LeadingAge

## Thank You

Jason Cleland, PharmD, BCGP Clinical Pharmacist- Patient Care

jason.cleland@optum.com

57



# References

- Bishop MF, Stephens L, Goodrich M, et al. Medication kits for managing symptomatic emergencies in the home: a survey of common hospice practice. J Paillat Med. 2009; 12(1): 37-44.
- Clary PL, Lawson P. Pharmacologic pearls for end-of-life care. Am Fam Physician. 2009;79(12):1059-1065
- Gonzales MJ, Widera E. Nausea and other nonpain symptoms in long-term care. Clin Geriatr Med. 2011;27:213-228.
   Harris D and Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992; 81(1): 1-10.
- Jungo KT, Rozsnyai Z, Mantelli S, et al. 'Optimising PharmacoTherapy In the multimorbid elderly in primary CAre' (OPTICA) to improve medication appropriateness: study protocol of a cluster randomised controlled trial. BMJ Open. 2019 Sep 3;9(9):e031080. doi: 10.1136/bmj0pen-2019-031080.
- Lexi-Drugs Online. Lexicomp. Wolters Kluwer; Hudson, OH. Accessed August 8, 2022.
- Leigh AE, Burgia KI, Williams BR, et al. Hospice emergency kit for veterans: a pilot study. J Palliot Med. 2013; 16(4): 336-361.
   Lindqvist O, Lundquist G, Dickman A, et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus optionion. J Palliot Med. 2013; 16(1): 346-361.
- Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternative routes of administration. J Pharm Sci. 2010: 99(1): 1-20.
- McLean SL, Blenkinsopp AJ, Bennett MI. Using haloperidol as an antimemtic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013; 27: 132-135.

References

- Omran 5, Khader Y, McMillan S. Symptom clusters and quality of life in hospice patients with cancer. Asian Pac J Cancer Prev 2017;18(9):2387-2393.
- Phongtankuel V, Teresi JA, Eimicke JP, Kong JX, Adelman RD, Prigerson HG, et al. Identifying the prevalence and correlates of caregiver-reported symptoms in home hospice patients at the end of life. J Palliat Med. 2020 May;23(5):635-640.
- Protus BM, Kimbrel J, Grauer P, eds. Palliative Care Consultant: Guidelines for Effective Management of Symptoms. 4th Edition. Montgomery, AL: HospiScript; 2015.
- Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med. 2007; 10(2): 465-475. Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2014;31(2):126-131.
- Tait P, Morris B, To T. Core palliative medicines: meeting the needs of non-complex community patients. Aust Fam Phys. 2014; 43: 29-32.
- Wowchuk SM, Wilson EA, Embleton L, et al. The palliative medication kit: an effective way of extending care in the home for patients nearing death. J Palliot Med. 2009; 12(9): 1-7.
- World Health Organization (WHO). Palliative Care. Accessed August 8, 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/palliative-care
- Yap R, Akhileswaran R, Heng CP, et al. Comfort care kit: use of nonoral and nonparenteral rescue medications at home for terminally ill patients with swallowing difficulty. J Polliot Med. 2014; 17(5): 575-578.

60

58

59

Leading Age